Skip to main content
fghjkjhb

Evidence gap analysis

Strategic analysis of the sufficiency of evidence to obtain reimbursement and HTA approval in Europe and recommendations about evidence generation

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Coverage positions published by the Dutch Healthcare Institute in Q2 2024

In the second quarter of 2024, the Dutch Healthcare Institute (ZIN) published four coverage positions on proton therapy in testicular cancer, pulmonary artery pressure remote monitoring in chronic heart failure, neuromodulation in polyneuropathy and physiotherapy and exercise therapy in primary care settings for lower back pain.

In the Position on proton therapy, published on April 10, 2024, the ZIN concluded that proton therapy for the prevention of second primary tumors can be reimbursed under basic health insurance in patients with testicular cancer. The reimbursement applies retroactively from February 01, 2022.

In the Position on pulmonary artery pressure remote monitoring, published on May 14, 2024, the ZIN concluded that it can be reimbursed under the basic health insurance in patients with chronic heart failure NYHA class III who have had at least one hospitalization due to heart failure in the past year. The reimbursement applies from May 14, 2024.

In the Position on physiotherapy and exercise therapy in primary care settings, published on June 25, 2024, the ZIN concluded that it cannot be reimbursed under the basic health insurance in patients with lower back pain without a specific physical cause as there is no evidence that treatment with physiotherapy and exercise therapy leads to pain relief, improvement of physical functioning, and quality of life compared to treatment without physiotherapy or exercise therapy.

In the Position on neuromodulation in chronic nerve pain, published on July 09, 2024, the ZIN concluded that neuromodulation via spinal cord stimulation or dorsal root ganglion stimulation can be reimbursed under the basic health insurance in patients with persistent severe pain due to polyneuropathy. The reimbursement will apply from July 09, 2024.

See more information in Dutch here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.